Eyegate Pharmaceuticals (EYEG) PT Set at $3.00 by HC Wainwright

HC Wainwright set a $3.00 price objective on Eyegate Pharmaceuticals (NASDAQ:EYEG) in a research report report published on Sunday, March 11th. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Separately, ValuEngine raised Eyegate Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, February 2nd.

Eyegate Pharmaceuticals (NASDAQ EYEG) opened at $0.61 on Friday. Eyegate Pharmaceuticals has a twelve month low of $0.50 and a twelve month high of $2.58. The firm has a market capitalization of $10.52, a price-to-earnings ratio of -0.65 and a beta of 3.37.

An institutional investor recently raised its position in Eyegate Pharmaceuticals stock. Vanguard Group Inc. grew its position in shares of Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) by 0.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 247,319 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,988 shares during the period. Vanguard Group Inc. owned approximately 2.27% of Eyegate Pharmaceuticals worth $339,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.48% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Eyegate Pharmaceuticals (EYEG) PT Set at $3.00 by HC Wainwright” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://stocknewstimes.com/2018/03/19/hc-wainwright-reiterates-3-00-price-target-for-eyegate-pharmaceuticals-eyeg.html.

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Receive News & Ratings for Eyegate Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply